Phase 3 Trial to Compare Enhertu to Kadcyla in HER2-Positive, High Risk Patients

Phase 3 Trial to Compare Enhertu to Kadcyla in HER2-Positive, High Risk Patients
Daiichi Sankyo and AstraZeneca are initiating a global Phase 3 trial to compare Enhertu (fam-trastuzumab deruxtecan-nxki) to Kadcyla (ado-trastuzumab emtansine, also called T-DM1) as adjuvant therapy in patients with HER2-positive early breast cancer, who remain at high risk of recurrence after neo-adjuvant therapy. These two types of therapy— adjuvant and neo-adjuvant — address different aspects of cancer treatment. Neo-adjuvant therapy aims to make tumors easier to remove by shrinking them before surgery. Adjuvant treatment aims to eradicate cancer cells that remain after surgery,  helping to lower the chance that the cancer returns. “Despite recent improvements and approvals of new medicines, there remain significant clinical needs for patients with HER2 positive early breast cancer with residual invasive disease after completing neo-adjuvant treatment. We recognize the important opportunity that exists post-surgery to slow disease progression with further adjuvant treatment,” Antoine Yver, MD, MSc, executive vice president of Daiichi Sankyo said in a press release. The open-label and randomized trial, named DESTINY-Breast05, will recruit patients with invasive cancer that remains in the breast or lymph nodes following neo-adjuvant treatment. These patients tend to have a higher risk of disease recurrence or death than those with no detecta
Subscribe or to access all post and page content.